Comparison of ultrasound guided injection of botulinum toxin at the origin of plantar fasciitis with injection of botulinum toxin by Babcock method in the treatment of plantar fasciitis

开始日期2023-09-23

申办/合作机构

Shahid Beheshti University of Medical Sciences

JPRN-jRCT1090220265

/ RecruitingN/AIIT

The study for the effect of botulinum toxin for upper limb spasticity - The effect of botulinum toxin for upper limb spasticity

开始日期2016-11-24

申办/合作机构

Higuchi, Inc.

NCT02674269

/ Withdrawn临床1/2期

A Randomized Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botulinum Toxin (Botox®) Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.

开始日期2016-10-01

申办/合作机构

UroGen Pharma Ltd.

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的专利（医药）

登录后查看更多信息

2,403

项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的文献（医药）

2026-05-01·Deutsches Arzteblatt International

Hyperhidrosis: Prevalence, Diagnosis, and Stepwise Treatment.

Review

作者: Rzany, Berthold ; Rapprich, Stefan ; Wiegering, Armin ; Schreiner, Waldemar

BACKGROUND:

Hyperhidrosis, or sweating beyond the physiological amount, can be either focal or generalized and sometimes runs in families. The prevalence of primary idiopathic hyperhidrosis is 2-5%. Secondary hyperhidrosis is associated with specific illnesses and medications. In this article, we discuss the diagnostic evaluation of hyperhidrosis and treatments for it, along with their efficacy and side effects.

METHODS:

This narrative review is based on publications retrieved from the Medline and Cochrane databases with the search term "hyperhidrosis" and other specific terms relating to treatment. Expert recommendations and guidelines were considered as well.

RESULTS:

The diagnostic evaluation consists of a clinical history, a Minor (starch-iodine) test, gravimetry, and dynamic sudometry. There have been no more than a few high-quality published studies on specific interventions. Depending on the severity and symptom burden, aluminum chloride and anticholinergic drugs are used first, followed by botulinum toxin injections and subcutaneous curettage for axillary hyperhidrosis. These treatments reportedly bring about marked improvement in 60-70 % of patients; their side effects, depending on the particular treatment used, include local reactions such as itch, pain, and cutaneous irritation and anticholinergic effects such as dry mouth, mydriasis, urinary retention, and headache. Further therapeutic options are tap water iontophoresis; radiofrequency, focused ultrasound, and microwave treatment; systemically administered anticholinergic drugs; and thoracic or lumbar sympathectomy for palmar or plantar hyperhidrosis, respectively.

CONCLUSION:

A variety of methods can be used to relieve hyperhidrosis and improve these patients' quality of life. There have been no more than a few high-quality studies on their efficacy and long-term results.

2026-03-01·BRITISH JOURNAL OF OPHTHALMOLOGY

Augmented medial rectus recession versus botulinum toxin therapy for acute acquired comitant esotropia: analysis of outcomes and recurrence predictors

Article

作者: Zhang, Wei ; Zhu, Ping ; Xie, Fang ; Li, Yueping ; Zhang, Tengyue ; Hao, Rui ; Chen, Liping ; Ding, Juan

Objective:

To compare the motor and sensory outcomes and quality of life (QOL) of augmented medial rectus recession (aMRc) and botulinum toxin A (BTXA) therapy in acute acquired comitant esotropia (AACE) treatment and to investigate the predictors of recurrence.

Methods:

We conducted a prospective, non-randomised clinical trial that enrolled 63 AACE patients with a disease course of 6 months to 2 years and deviation angles of 15 to 60 prism diopters. The patients were assigned to BTXA (n=31) and aMRc group (n=32). We compared and analysed the deviation angles, fusion amplitudes (FA) of convergence and divergence, stereopsis, and scores of QOL and diplopia between the two groups before treatment and at 2, 4, 6 and 12 months post-treatment.

Results:

Both groups exhibited significant improvements in motor and sensory outcomes. The aMRc group showed more stable and satisfactory deviation than the BTXA group at 6 and 12 months post-treatment, with a significant increase in divergent FA. The aMRc group achieved a higher success rate (93.75%) than the BTXA group (64.52%) 1 year post-treatment. QOL improved significantly in both groups after treatment, except for reading function in the BTXA group. Compared with the BTXA group, the aMRc group showed greater improvements in self-perception, general function, and diplopia scores (p<0.05). Survival analysis revealed a significant difference between the two groups (p=0.0046). Treatment method and convergent FA at near before treatment were identified as recurrence predictors (p=0.023 and 0.025).

Conclusions:

Augmented MRc treatment was superior to BTXA injection in AACE patients with courses >6 months during 1-year observation, particularly in maintaining alignment, eliminating diplopia and improving divergent FA and QOL.

Trial registration number:

ChiCTR2300068735.

2026-03-01·PAIN

Noninvasive cranial suture stimulation: exploring the functional extracranial–intracranial trigeminal fibre connection in humans

Article

作者: Thieleke, Alexandra ; May, Arne ; Peng, Kuan-Po

Abstract:

Recent evidence suggests that cranial sutures could serve as conduits for nociceptive transmission from extracranial to intracranial fibres, potentially influencing headache pathophysiology. Animal studies indicate extracranial stimulation affects dural nerve activity, and suture-targeted therapies like botulinum toxin show efficacy in chronic migraine. However, the role of the “suture pathway” in human headache generation remains unclear. This study investigates whether extracranial stimulation over cranial sutures induces more intracranial activation, ie, headache generation, than stimulation at nonsutural sites. Sixty healthy participants from 3 cohorts (n = 20 each) received noninvasive capsaicin or electrical stimulation at sutural and nonsutural sites in a pseudorandomised parallel-group crossover design. Headache occurrence, intensity, and duration were compared. The 3 study cohorts were comparable in terms of the sex and age distribution (50% being female, with an average age between 25 and 30 years). After stimulation, the incidence of headaches at the suture site point was 35%, 60%, and 25% in cohorts 1, 2, and 3, respectively. No significant difference was found between sutural and nonsutural sites ( P > 0.05 in all 3 cohorts). The functional relevance of the sutural pathway remains inconclusive in humans. Although extracranial stimulation indeed may result in headache, this effect appears to be independent of the stimulation sites. Adjacent structures, including epicranial muscles, may modulate the headache induction rate. The functional role of the connection may be different in patients with headache than in healthy controls. Future research should explore these mechanisms using an optimised stimulation protocol, with a focus on patients with headache.

项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的新闻（医药）

2025-12-15

·Business Wire

Trends Shaping the $5 Billion Spasticity Treatment Market, 2026-2034: Focus on Multimodal Care and Treatment Innovations - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spasticity Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering. The global Spasticity Treatment Market, valued at USD 5.02 billion in 2025, is set to expand at a CAGR of 5.5%, reaching USD 8.13 billion by 2034. This growth is driven by innovations in pharmacologic therapies, interventional procedures, and multimodal rehabilitative modalities designed to manage spasticity associated with various neurological conditions. Key areas of focus include post-stroke rehabilitation, cerebral palsy, multiple sclerosis, spinal cord injuries, and traumatic brain injuries. The market is marked by a shift towards personalized treatment approaches, whereby oral antispasmodics, botulinum toxin injections, and intrathecal baclofen pumps are tailored to individual patient needs. Image-guided chemodenervation, device miniaturization, and remote monitoring are emerging trends enhancing treatment efficacy and patient outcomes. Key drivers of market growth include increased stroke survival rates, aging populations, improved diagnosis of pediatric neuromotor disorders, and payer recognition of treatments that reduce falls, contractures, and caregiver burden. Providers are distinguishing themselves through multidisciplinary clinics, reduced wait times, and protocolized treatments that emphasize measurable improvements in patient mobility and quality of life. In terms of regional insights, North America leads with comprehensive neurorehabilitation networks, Europe sees guideline-driven practices with strong focal injection adoption, and the Asia-Pacific region is expanding access due to rising MS awareness and growing pediatric neurology services. Meanwhile, Middle East & Africa and South & Central America are witnessing investments in rehabilitation infrastructure and caregiver education programs. The Spasticity Treatment Market segmented by type includes drug therapy, physical therapy, and surgical treatment, while end-users comprise hospitals, ambulatory surgical centers, specialty clinics, and diagnostic centers. Prominent market players include Amcor plc, Silgan Holdings, Inc., and Ardagh Group. The competitive space is characterized by strategic initiatives such as mergers, technology collaborations, and regional expansions that aim to advance product innovation and market reach. The report addresses market size forecasts, growth potential across segments, supply chain adaptations, and the impact of geopolitical shocks like the Russia-Ukraine conflict on trade and costs. Key Attributes Key Topics Covered 1. Table of Contents 2. Global Spasticity Treatment Market Summary, 2025 2.1 Spasticity Treatment Industry Overview 2.2 Spasticity Treatment Market Scope 2.3 Research Methodology 3. Spasticity Treatment Market Insights, 2024-2034 3.1 Spasticity Treatment Market Drivers 3.2 Spasticity Treatment Market Restraints 3.3 Spasticity Treatment Market Opportunities 3.4 Spasticity Treatment Market Challenges 3.5 Tariff Impact on Global Spasticity Treatment Supply Chain Patterns 4. Spasticity Treatment Market Analytics 4.1 Spasticity Treatment Market Size and Share 4.2 Five Forces Analysis for Global Spasticity Treatment Market 5. Global Spasticity Treatment Market Statistics 6. Asia Pacific Spasticity Treatment Industry Statistics 6.1 Asia Pacific Spasticity Treatment Market Insights 6.2 Asia Pacific Spasticity Treatment Market Revenue Forecast 6.3 Asia Pacific Spasticity Treatment Market Revenue Forecast by Country 7. Europe Spasticity Treatment Market Data 7.1 Europe Spasticity Treatment Market Key Findings 7.2 Europe Spasticity Treatment Market Size and Percentage Breakdown 7.3 Europe Spasticity Treatment Market Size and Percentage Breakdown by Country 8. North America Spasticity Treatment Market Size, Growth Trends, and Future Prospects 8.1 North America Snapshot 8.2 North America Spasticity Treatment Market Analysis and Outlook 8.3 North America Spasticity Treatment Market Analysis and Outlook by Country 9. South and Central America Spasticity Treatment Market Drivers, Challenges, and Future Prospects 9.1 Latin America Spasticity Treatment Market Data 9.2 Latin America Spasticity Treatment Market Future 9.3 Latin America Spasticity Treatment Market Future by Country 10. Middle East Africa Spasticity Treatment Market Outlook and Growth Prospects 10.1 Middle East Africa Overview 10.2 Middle East Africa Spasticity Treatment Market Statistics 10.3 Middle East Africa Spasticity Treatment Market Statistics by Country 11. Spasticity Treatment Market Structure and Competitive Landscape 11.1 Key Companies in Spasticity Treatment Industry 11.2 Spasticity Treatment Business Overview 11.3 Spasticity Treatment Product Portfolio Analysis 11.4 Financial Analysis 11.5 SWOT Analysis Key Companies Featured For more information about this report visit https://www.researchandmarkets.com/r/aj5h9l About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

2024-11-21

·Medical Design and Outsourcing

Merz Therapeutics and S3 Connected Health launch iFlexo

NEWS RELEASE: Merz Therapeutics and S3 Connected Health Pioneer New Digital Health Solution, iFlexo, for People Living with Post-Stroke Spasticity Dublin/Frankfurt — Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity as part of its ongoing commitment to supporting stroke survivors. The app, developed in collaboration with S3 Connected Health, provides targeted exercises and rehabilitation programs specifically aimed at improving mobility for those with mild to moderate spasticity. By offering guided routines, iFlexo aims to help stroke survivors regain independence and improve their overall quality of life. Merz Therapeutics is the first and only neurotoxins pharmaceutical company to offer a platform to support self-rehabilitation. iFlexo, developed and operated on S3 Connected Health’s digital health platform Affinial, was released in August 2024 and is available for iOS and Android in France. Developing iFlexo on Affinial enabled the creation of a differentiated user experience optimized for post-stroke patients. An accelerated time to market of just five months was achieved thanks to Affinial’s range of pre-built, customizable digital health services. The Affinial platform enables iFlexo to scale and evolve by addressing current and future compliance, legal, cybersecurity, and regulatory requirements. During the pilot stage in France, it gained significant interest from patients, clinicians, and key opinion leaders. Dr. Alexandre Bertholon, Physical Medicine & Rehabilitation at Le Clos Champirol, says: “iFlexo is a promising solution in physical rehabilitation, offering a much-needed response to the current challenges in the field. It enables patients to engage in self-rehabilitation at home, focusing on their personal goals. This platform not only supports patients but also enhances efficiency for healthcare professionals by optimizing and extending the results of rehabilitation. It demonstrates how new solutions can improve patient outcomes and make care more effective.” Up to one-third of stroke survivors experience spasticity, a condition that can severely limit their ability to perform everyday tasks, often leaving them reliant on others.[1] For these individuals, personalized botulinum neurotoxin injection therapy as part of a multimodal approach can improve muscle tone and consequently patient’s mobility and quality of life. [2] Merz Therapeutics and S3 Connected Health are committed to providing better outcomes for more patients and are currently working on expanding the solution to more countries, starting in the coming months. [1] Ali, A., McCarthy, A.D., Reeves, M. et al. Sheffield Adaptive Patterned Electrical Stimulation (SHAPES) Therapy for Post Stroke Arm spasticity: study protocol for a 3-arm, a partially blinded, randomised controlled trial. BMC Neurol 24, 437 (2024). [2] Otero-Luis I, Martinez-Rodrigo A, Cavero-Redondo I, Moreno-Herráiz N, Martínez-García I, Saz-Lara A. Effect of Botulinum Toxin Injections in the Treatment of Spasticity of Different Etiologies: An Umbrella Review. Pharmaceuticals. 2024; 17(3):310. Merz Therapeutics Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs. For more information, please visit: S3 Connected Health S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company’s scalable and secure solutions improve disease management, differentiate pharmaceutical products and deliver new therapeutic approaches. Affinial, S3 Connected Health’s digital health platform, offers partners the opportunity to develop customized digital health solutions tailored to specific patient, device or disease needs. The platform’s pre-built services provide best practice implementation to ensure successful solution adoption and an accelerated time-to-market. For more information, please visit: The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.

2024-05-21

·PRNewswire

Guidance for Common Post-stroke Condition of Spasticity Released by the American Academy of Physical Medicine and Rehabilitation

ROSEMONT, Ill., May 21, 2024 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has today released spasticity guidance to establish a framework that reviews treatment options, endorses the highest quality of evidence-based care, and encourages research where there are knowledge gaps. Spasticity is a group of symptoms characterized by muscle tightening or reduced stretchability following injuries to or conditions affecting the brain and spinal cord, including stroke, cerebral palsy, multiple sclerosis, traumatic brain injury, or spinal cord injuries. Continue Reading When spasticity symptoms are recognized early, physicians can better manage and treat it through a range of therapies. Post this Spasticity symptoms include uncontrollable rhythmic, shaking movements, cramping, spasms, and tight, rigid muscles that cannot be stretched easily and may cause pain. Other symptoms may include incoordination, fatigue, weakness, and impaired motor control. Spasticity is often delayed and an evolving condition. If left untreated, spasticity can cause muscles to become stuck, leading to joint deformity. "Physicians have a growing toolbox of treatments for spasticity," said guidance author Dr. Preeti Raghavan, MBBS. "When patients or their caregivers recognize the symptoms of spasticity and seek treatment for those symptoms, we have even better chances to manage and treat their spasticity symptoms through a range of therapies." The first line of treatment and management interventions aimed at reducing the effects of spasticity is rehabilitative therapy. Simple, non-pharmacologic interventions that facilitate movement and improve function should be attempted before resorting to treatments that carry more risks and side effects. Therapeutic interventions can be used individually or in combination, including oral medications, injectables such as Botulinum toxin, and surgical options. An integrated, multi-disciplinary, goal-centered management approach is essential to providing long-term, comprehensive care for spasticity. PM&R physicians are leaders in recovery and regularly care for patients with conditions that cause spasticity, such as rehabilitating patients post-stroke or other conditions causing spasticity. Because of this, PM&R physicians have the necessary specialized equipment, supplies, and prior authorization procedures in place to treat spasticity patients and work with their insurance providers. The guidance is published in the PM&R Journal. The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians specializing in physical medicine and rehabilitation. PM&R physicians, also known as physiatrists, treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles and tendons. PM&R physicians evaluate and treat injuries, illnesses and disability and are experts in designing comprehensive, patient-centered treatment plans. Physiatrists utilize cutting-edge as well as time-tested treatments to maximize function and quality of life. SOURCE American Academy of Physical Medicine and Rehabilitation

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Botulinum toxin(UroGen Pharma Ltd.)	M03AX01	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尿失禁	临床2期	以色列	UroGen Pharma Ltd.	2016-10-01
膀胱过度活动症	临床2期	以色列	UroGen Pharma Ltd.	2016-10-01
间质性膀胱炎	临床2期	-	UroGen Pharma Ltd.	-
间质性膀胱炎	临床2期	-	Allergan UC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDS2022	N/A	面肌痉挛	7	Patients receiving Botulinum toxin Injections	鏇觸壓廠膚鬱餘醖鹽蓋(積願廠鬱衊醖製憲膚獵) = 鬱選窪膚獵憲積餘顧糧淵糧艱餘衊窪構壓鏇網 (醖獵蓋窪選鹽蓋鹽積築 )	积极	2022-09-15
APAO2019	N/A	良性基础型眼睑痉挛	-	Botulinum Toxin 25 IU	憲簾憲範選淵顧鬱鑰窪(遞夢夢築簾餘築獵範範) = 積糧衊築築築遞廠鹽壓顧窪網願構選簾範襯蓋 (醖顧醖簾獵淵獵簾艱獵 ) 更多	-	2019-03-06
Pubmed	N/A	盆底功能障碍	30	Botulinum toxin type A	選齋選構鹹齋鑰憲製簾(襯顧鑰衊醖鏇鬱觸窪顧) = 繭觸網構製觸積醖網廠鏇憲齋鬱範製夢獵壓遞 (繭顧醖網願憲範糧觸簾 ) 更多	积极	2009-01-03
Pubmed	N/A	盆底功能障碍	30	botulinum toxin (Partial division of puborectalis)	選齋選構鹹齋鑰憲製簾(襯顧鑰衊醖鏇鬱觸窪顧) = 襯廠範憲觸鏇網鏇艱網鏇憲齋鬱範製夢獵壓遞 (繭顧醖網願憲範糧觸簾 ) 更多	积极	2009-01-03